Tests clot removal plus standard care for severe acute stroke
Tests clot removal with standard medicines in adults with large stroke and blocked artery.
Plain-language title generated from the registry record
Registry title: Endovascular Treatment for eXtra-Large Ischemic Stroke
Key facts
- Where
- Hengyang and Xiangtan, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke caused by a blocked large brain artery and a very large area of damaged brain tissue.
- Age
- 18 years or older. People 80 years or older can join only with a modified Rankin scale score of 0 or 1.
- Sex
- All sexes can join.
- Disease stage
- Acute stroke from a blockage of the internal carotid artery or the M1 or M2 part of the middle cerebral artery, within 6 hours from last known well. Later or unknown timing needs a negative MRI-FLAIR with infarct on MRI-DWI. Baseline ASPECTS score of 0-2 or infarct core volume of 100ml or more.
Main reasons for not taking part
- Bleeding seen on CT or MRI
- Brain swelling with midline shift or herniation on baseline imaging
- Blood vessels too twisted for the thrombectomy device to reach the blockage
- History of bleeding disorders, severe heart, liver or kidney disease, or sepsis
- Terminal illness with life expectancy under 6 months
Read by machine on 12 November 2026.
Where in China
- The First Affiliated Hospital, Hengyang Medical School, University of South ChinaHengyang, ChinaContact: Zhongfan RuanTaking people
- Xiangtan Central HospitalXiangtan, ChinaContact: Guangxiong YuanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhongming Qiu
- Trial code
- NCT06388148
- Record updated
- 26 December 2025
- Original description
The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.Read full original descriptionShow less
Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial
The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.
Inclusion: Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older; Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if > 6 hours or unknown last known well time; Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA/MRA/DSA; Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml; The patient or patient's representative signs a written informed consent form.
Exclusion: Currently participating in another investigational drug study; CT or MR evidence of hemorrhage; History of bleeding disorders, severe heart, liver or kidney disease, or sepsis; Any terminal illness with life expectancy less than 6 months; Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging; Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access.